Check out our most popular compounded medications! Get Started
Cinacalcet 5 mg/mL Oral Suspension is a liquid dosage form where the active ingredient, cinacalcet, is uniformly dispersed in a liquid medium, ensuring a homogeneous mixture for precise administration. This formulation is primarily used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Cinacalcet 5 mg/mL Oral Suspension is a customized liquid medication formulated to manage conditions associated with elevated parathyroid hormone (PTH) levels, such as secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism when surgical intervention is not an option.
This liquid dosage form provides an alternative for patients who have difficulty swallowing tablets or require precise dosing adjustments. By dispersing the active ingredient uniformly throughout the liquid medium, the suspension ensures consistent dosing with each administration, enhancing therapeutic efficacy and patient compliance.
Cinacalcet works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid gland to extracellular calcium. This action leads to decreased secretion of PTH, ultimately reducing serum calcium and phosphorus levels. Controlling PTH levels is crucial in preventing complications such as bone disease and cardiovascular calcification associated with chronic kidney disease.
For patients, it is important to take this medication exactly as prescribed by your healthcare provider. Shake the bottle well before each use to ensure the medication is evenly distributed. Use a proper measuring device to ensure accurate dosing. Potential side effects may include nausea, vomiting, low calcium levels (hypocalcemia), and muscle cramps. Regular monitoring of calcium and phosphorus levels is essential during treatment to adjust dosing and minimize adverse effects.
Prescribers should consider the individualized dosing requirements when prescribing Cinacalcet Oral Suspension. Starting doses and titration should be based on serum calcium and PTH levels. The compounding of this suspension allows for
Cinacalcet is a calcimimetic agent primarily used to treat conditions such as secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. When considering the use of Cinacalcet 5 mg/mL Oral Suspension, it is crucial to be aware of potential drug interactions that may affect the efficacy and safety of the treatment.
Cinacalcet is metabolized primarily by the cytochrome P450 enzyme CYP3A4, and to a lesser extent by CYP1A2 and CYP2D6. Therefore, drugs that inhibit or induce these enzymes can significantly alter the plasma concentration of cinacalcet. Strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin, may increase cinacalcet levels, potentially leading to an increased risk of adverse effects such as hypocalcemia. Conversely, CYP3A4 inducers like rifampin and phenytoin may decrease cinacalcet levels, reducing its therapeutic efficacy.
Additionally, cinacalcet is a potent inhibitor of CYP2D6. Caution is advised when it is co-administered with drugs that are metabolized by CYP2D6, especially those with a narrow therapeutic index, such as tricyclic antidepressants, beta-blockers, and certain antiarrhythmics. The interaction may lead to increased plasma concentrations of these drugs, necessitating dose adjustments and careful monitoring for adverse effects.
Patients taking medications that can lower serum calcium levels, such as bisphosphonates or loop diuretics, should be monitored closely when starting cinacalcet, as the combination may exacerbate hypocalcemia. Regular monitoring of serum calcium levels is recommended to ensure they remain within the target range and to adjust the cinacalcet dose as necessary.
Furthermore, cinacalcet may interact with other medications that affect cardiac conduction, such as antiarrhythmics and certain antipsychotics, due to its potential to cause hypocalcemia, which can prolong the QT interval. Patients on such medications should be monitored for signs of cardiac arrhythmias, and ECG monitoring may be warranted in some cases.
For both patients and prescribers, it is essential to review all current medications, including over-the-counter drugs and supplements, to identify potential interactions before starting cinacalcet. If you have any questions or need further information regarding drug interactions with Cinacalcet 5 mg/mL Oral Suspension, please reach out to us at Bayview Pharmacy. We are here to assist you in ensuring safe and appropriate use of this medication.
Cinacalcet 5 mg/mL Oral Suspension is a liquid dosage form designed to provide a uniform and homogeneous mixture of the active ingredient, cinacalcet, dispersed throughout a liquid medium. This formulation is particularly beneficial for patients who have difficulty swallowing tablets or require precise dosing adjustments. The oral suspension allows for flexible dosing, which can be tailored to the specific needs of the patient, ensuring optimal therapeutic outcomes.
Cinacalcet is a calcimimetic agent that works by modulating the activity of the calcium-sensing receptors (CaSR) on the surface of the parathyroid gland. These receptors play a crucial role in regulating parathyroid hormone (PTH) secretion. By enhancing the sensitivity of these receptors to extracellular calcium, cinacalcet effectively reduces the levels of PTH, calcium, and phosphorus in the blood. This mechanism of action is particularly useful in treating conditions such as secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, and hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism when parathyroidectomy is not an option.
For patients with secondary hyperparathyroidism, cinacalcet helps to manage the overproduction of PTH, which can lead to bone disease and cardiovascular complications. By lowering PTH levels, cinacalcet helps to maintain bone health and reduce the risk of cardiovascular events. In cases of hypercalcemia associated with parathyroid carcinoma or primary hyperparathyroidism, cinacalcet effectively lowers elevated calcium levels, thereby alleviating symptoms and preventing complications associated with hypercalcemia.
The liquid formulation ensures that the medication is evenly distributed, allowing for accurate dosing and consistent therapeutic effects. Patients and prescribers can benefit from the flexibility of dosing adjustments, which can be made based on the patient's response and laboratory results.
If you have any questions or require further information about Cinacalcet 5 mg/mL Oral Suspension, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any inquiries or concerns you may have regarding this formulation and its use in treating the specified disease states.
Cinacalcet 5 mg/mL Oral Suspension is a liquid dosage form where the active ingredient, Cinacalcet, is uniformly dispersed in a liquid medium to create a homogeneous mixture for easy administration.
Store Cinacalcet Oral Suspension at room temperature, away from direct sunlight and moisture. Ensure the bottle is tightly closed when not in use to maintain its stability and effectiveness.
Administer the prescribed dose of Cinacalcet Oral Suspension using a calibrated measuring device, such as an oral syringe or dosing cup, to ensure accuracy. Follow your healthcare provider's instructions for dosage and frequency.
It is generally recommended to administer Cinacalcet Oral Suspension directly without mixing it with food or drinks to ensure the full dose is consumed. Consult your healthcare provider for specific instructions.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
Common side effects may include nausea, vomiting, and dizziness. If you experience severe side effects or signs of an allergic reaction, contact your healthcare provider immediately.
Cinacalcet Oral Suspension may be prescribed for children under specific circumstances. Always follow the guidance of a healthcare provider regarding its use in pediatric patients.
Consult your healthcare provider before using Cinacalcet Oral Suspension if you are pregnant or breastfeeding, as they can provide guidance based on your specific situation and health needs.
Cinacalcet works by decreasing levels of parathyroid hormone (PTH), calcium, and phosphorus in the body, which helps manage conditions like secondary hyperparathyroidism and parathyroid carcinoma.
If you suspect an overdose, seek immediate medical attention. Symptoms of overdose may include muscle spasms, tingling, or numbness. It is important to follow the prescribed dosage to avoid complications.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
